CANY
ARCT icon

Caxton Associates (New York)’s Arcturus Therapeutics ARCT Stock Holding History

Caxton Associates (New York)’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,967
Closed -$202K – 475
2024
Q1 		$202K Buy
+5,967
New +$211K 0.01% 426

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caxton Associates (New York)'s ARCT Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 5,967 shares — an estimated $202K sold.

Caxton Associates (New York) first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $202K in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 5,967 Arcturus Therapeutics shares in Q2 2024, an estimated $202K.
  • Caxton Associates (New York) first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Caxton Associates (New York)'s Arcturus Therapeutics position peaked at $202K in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.